Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Alexander P. J. Vlaar(University of Amsterdam), Pieter van Paassen(Maastricht University Medical Centre), Matthijs C. Brouwer(University of Amsterdam), José Francisco Kerr Saraiva(British Heart Foundation), Robert Zerbib(Inflarx (Germany)), Alexander D. Cornet(Medisch Spectrum Twente), Korinna Pilz(Inflarx (Germany)), Martin Witzenrath(Humboldt-Universität zu Berlin), Anastasia Grebenyuk(City Clinical Hospital), Leo Heunks(Radboud University Nijmegen), Pieter R. Tuinman(Amsterdam University Medical Centers), Johannes Engelbrecht(Right to Care), Gernot Marx(RWTH Aachen University), Philippe G. Jorens(University of Antwerp), Endry H. T. Lim(Amsterdam Neuroscience), Niels C. Riedemann(Inflarx (Germany)), Rodrigo Boldo(Hospital Mãe de Deus), Murimisi Mukansi(University of the Witwatersrand), Bruno Mourvillier(Université Claude Bernard Lyon 1), Sanne de Bruin(Amsterdam University Medical Centers), Johannes M. Engelbrecht(Right to Care), Jesus Abraham Simón Campos, Suzana M. Lobo(Faculdade de Medicina de São José do Rio Preto), Renfeng Guo, Simon Rückinger, Jesus Simon-Campos, Diederik van de Beek(Amsterdam Neuroscience)
Cited by 143
Related Papers
Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury
|Critical Care|2013|1.4k
Epidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis
|Clinical Microbiology Reviews|2010|922
ESCMID guideline: diagnosis and treatment of acute bacterial meningitis
|Clinical Microbiology and Infection|2016|899
Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study
|The Lancet Respiratory Medicine|2020|864